AZ third big pharma to strike deal for Immunocore's T-Cell technology
This article was originally published in Scrip
Executive Summary
And MedImmune makes three for privately own Immunocore. The up and coming biotechnology firm based in Oxford, UK, has signed another drug discovery deal for its T-cell technology, ImmTACs.